[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abcellera Biologics Inc (ABCL)

Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,489,233
  • Shares Outstanding, K 306,611
  • Annual Sales, $ 75,130 K
  • Annual Income, $ -146,410 K
  • EBIT $ -200 M
  • EBITDA $ -171 M
  • 60-Month Beta 1.20
  • Price/Sales 44.77
  • Price/Cash Flow N/A
  • Price/Book 3.74

Options Overview Details

View History
  • Implied Volatility 87.80% (+2.34%)
  • Historical Volatility 116.01%
  • IV Percentile 12%
  • IV Rank 5.08%
  • IV High 335.35% on 02/04/26
  • IV Low 74.55% on 12/24/25
  • Expected Move (DTE 4) 0.94 (8.22%)
  • Put/Call Vol Ratio 0.41
  • Today's Volume 20,487
  • Volume Avg (30-Day) 8,568
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 162,176
  • Open Int (30-Day) 154,148
  • Expected Range 10.45 to 12.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.18
  • Number of Estimates 2
  • High Estimate $-0.17
  • Low Estimate $-0.18
  • Prior Year $-0.19
  • Growth Rate Est. (year over year) +5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.98 +128.51%
on 07/28/26
11.50 -1.04%
on 08/14/26
+4.64 (+68.84%)
since 07/14/26
3-Month
3.94 +188.83%
on 05/19/26
11.50 -1.04%
on 08/14/26
+6.98 (+158.64%)
since 05/14/26
52-Week
2.74 +314.57%
on 02/05/26
11.50 -1.04%
on 08/14/26
+6.88 (+152.89%)
since 08/14/25

Most Recent Stories

More News
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

AbCellera Biologics Inc. (Nasdaq: ABCL) (“AbCellera”) today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per...

ABCL : 11.38 (+3.74%)
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera Biologics Inc. (Nasdaq: ABCL) (“AbCellera”) today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain...

ABCL : 11.38 (+3.74%)
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single dose ABCL635 significantly...

ABCL : 11.38 (+3.74%)
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

Management to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ET

ABCL : 11.38 (+3.74%)
AbCellera Reports Q2 2026 Business Results

AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated....

ABCL : 11.38 (+3.74%)
AbCellera's Revenue Trajectory Hinges on Partnership Disclosures That May Not Come

Barchart Research What to Expect from ABCL Earnings ABCL Generated August 4, 2026 Current Price $6.09 EPS Estimate $$-0.17 Consensus Rating Strong Buy Average Move 5.83% AbCellera's Revenue Trajectory...

ABCL : 11.38 (+3.74%)
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

AbCellera (Nasdaq: ABCL) today announced a collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers...

ABCL : 11.38 (+3.74%)
VRTX : 505.75 (-2.07%)
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

AbCellera (Nasdaq: ABCL) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern...

ABCL : 11.38 (+3.74%)
AbCellera Appoints Dr. Lynn Seely to its Board of Directors

AbCellera (Nasdaq: ABCL) today announced the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director. “Dr. Seely is a respected executive leader with...

ABCL : 11.38 (+3.74%)
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises options to develop

ABCL : 11.38 (+3.74%)
JAZZ : 244.96 (-0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635 and ABCL575. AbCellera Biologics Inc. is based in Vancouver, Canada.

See More

Key Turning Points

3rd Resistance Point 12.79
2nd Resistance Point 12.15
1st Resistance Point 11.76
Last Price 11.38
1st Support Level 10.73
2nd Support Level 10.09
3rd Support Level 9.70

See More

52-Week High 11.50
Last Price 11.38
Fibonacci 61.8% 8.16
Fibonacci 50% 7.12
Fibonacci 38.2% 6.09
52-Week Low 2.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.